Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16241
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAckermann, Uwe-
dc.contributor.authorLewis, Jason S-
dc.contributor.authorYoung, Kenneth-
dc.contributor.authorMorris, Michael J-
dc.contributor.authorWeickhardt, Andrew-
dc.contributor.authorDavis, Ian D-
dc.contributor.authorScott, Andrew M-
dc.date2016-07-04-
dc.date.accessioned2016-09-13T02:00:06Z-
dc.date.available2016-09-13T02:00:06Z-
dc.date.issued2016-08-
dc.identifier.citationJournal of Labelled Compounds and Radiopharmaceuticals 2016; 59(10): 424-428en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16241-
dc.description.abstractImaging of androgen receptor expression in prostate cancer using F-18 FDHT is becoming increasingly popular. With the radiolabelling precursor now commercially available, developing a fully automated synthesis of [(18) F] FDHT is important. We have fully automated the synthesis of F-18 FDHT using the iPhase FlexLab module using only commercially available components. Total synthesis time was 90 min, radiochemical yields were 25-33% (n = 11). Radiochemical purity of the final formulation was > 99% and specific activity was > 18.5 GBq/µmol for all batches. This method can be up-scaled as desired, thus making it possible to study multiple patients in a day. Furthermore, our procedure uses 4 mg of precursor only and is therefore cost-effective. The synthesis has now been validated at Austin Health and is currently used for [(18) F]FDHT studies in patients. We believe that this method can easily adapted by other modules to further widen the availability of [(18) F]FDHT.en_US
dc.titleFully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab moduleen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleJournal of Labelled Compounds and Radiopharmaceuticalsen_US
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.affiliationSchool of Cancer Medicine, LaTrobe University, Bundoora, Victoria, Australiaen_US
dc.identifier.affiliationRadiochemistry & Molecular Imaging Probe Core, Memorial Sloan Kettering Cancer Center, New York, NY, USAen_US
dc.identifier.affiliationGenitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USAen_US
dc.identifier.affiliationMonash University Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationEastern Health, Melbourne, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/27378195en_US
dc.identifier.doi10.1002/jlcr.3417en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-9066-8244en_US
dc.identifier.orcid0000-0002-6656-295Xen_US
dc.type.austinJournal Articleen_US
local.name.researcherAckermann, Uwe
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Nov 21, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.